Tiburon, CA, United States of America

Christopher D Thanos

USPTO Granted Patents = 57 

 

 

Average Co-Inventor Count = 3.2

ph-index = 9

Forward Citations = 291(Granted Patents)

Forward Citations (Not Self Cited) = 214(Oct 12, 2025)


Location History:

  • Providence, RI (US) (2003 - 2004)
  • San Francisco, CA (US) (2013 - 2015)
  • Burlingame, CA (US) (2021)
  • Cumberland, RI (US) (2004 - 2024)
  • Tiburon, CA (US) (2016 - 2024)

Company Filing History:


Years Active: 2003-2025

Loading Chart...
Loading Chart...
Loading Chart...
57 patents (USPTO):

Title: Christopher D. Thanos: Pioneering Innovations in Cancer Immunotherapy

Introduction: Christopher D. Thanos, based in Tiburon, CA, is a distinguished innovator in the field of biotechnology, holding an impressive 52 patents. His contributions primarily focus on engineered immunostimulatory bacterial strains that hold significant promise in the realm of cancer therapy.

Latest Patents: Among his most recent patents is a groundbreaking invention titled "Engineered Immunostimulatory Bacterial Strains and Uses Thereof." This patented technology involves the development of delivery immunostimulatory bacteria designed to enhance tumor colonization and anti-tumor activity. The bacteria are meticulously modified by the deletion or alteration of genes encoding flagella and pagP, leading to unique properties that enable improved function in the tumor microenvironment. Additionally, these immunostimulatory bacteria are engineered to possess benefits such as reduced cell death in immune cells and improved targeting of immune cells in cancerous tissues, thereby offering novel methods for inhibiting the growth and volume of solid tumors via their administration.

Career Highlights: Thanos has made significant strides in the biotechnology industry, contributing to major advancements in cancer treatment. His work with companies such as Sutro Biopharma, Inc. and Catalyst Biosciences, Inc. underscores his integral role in pioneering research and application of immunotherapy approaches.

Collaborations: Throughout his career, Christopher has collaborated with talented professionals including Edwin L. Madison and Ryan Stafford. These collaborations have facilitated the cross-pollination of ideas and innovations that are crucial in developing effective therapeutic strategies.

Conclusion: Christopher D. Thanos exemplifies the spirit of innovation within the biotechnology sector. His extensive patent portfolio and collaborative efforts highlight the significant impact of his work in cancer immunotherapy. As research continues to advance, his contributions will undoubtedly play a critical role in shaping the future of cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…